![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Healthcare Ent. | LSE:HCEG | London | Ordinary Share | GB00B6030H73 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:1452B Healthcare Enterprise Group PLC 23 July 2004 Healthcare Enterprise Group PLC Increased shareholding in Ebiox Limited Healthcare Enterprise Group PLC ("HCEG" or the "Group"), the healthcare products and services company, has acquired an approximate further 2% in Ebiox Limited (" Ebiox") giving HCEG an effective majority holding of 51% of Ebiox, which owns a range of proprietary cleansing and decontamination products for use in the healthcare industry. HCEG will pay #50,000 in cash and #35,000 in HCEG shares to Keith MacGregor, the vendor, contingent upon the achievement of specific agreed "milestones". These milestones relate to, amongst other things, the further testing of the product. Furthermore, HCEG has granted four put options to the vendor to require HCEG to purchase the remaining 49% of the share capital of Ebiox in four tranches contingent upon the achievement of further agreed milestones. The consideration payable upon exercise of each put option will be #250,000 to be satisfied in cash, or by the issuance of HCEG shares, for each of the four tranches. The vendor has also agreed to grant HCEG a call option to acquire the remaining share capital of Ebiox so as to give HCEG an effective 100% of the share capital of Ebiox. The consideration payable upon exercise of the call option will be up to #1,000,000 to be satisfied in cash, or by the issuance of HCEG shares. The put and call arrangements are in substitution for the option arrangements entered into in February 2004 and announced at that time. In the year end to 31 March 2003, the latest date for which accounts are available, Ebiox made a loss of #51,161 on turnover of #57,643. Stuart Bruck, Executive Chairman, Healthcare Enterprise Group PLC, commented: "Ebiox products are already being used in 50 National Health Service hospitals in the UK and has achieved a range of important milestones, which makes this an attractive transaction for HCEG. Moreover, this new deal gives HCEG effective control over the development of this exciting range of world class products. It also provides for the outright acquisition of Ebiox once it has produced the relevant results." 23 July 2004 Enquiries: Healthcare Enterprise Group 020 7351 7500 Stuart Bruck, Executive Chairman Gordon Wood, Group Chief Operating Officer College Hill 020 7457 2020 Nicholas Nelson Corinna Dorward Notes to Editors Ebiox Ebiox produces a range of patented cleansing, decontamination and disinfectant products. The range includes hand hygiene products, hard surface cleaners, disinfectants and products to clean and decontaminate surgical instruments. The Ebiox antibacterial handwash and handrub are proven effective against MRSA, E-coli and other important pathogens and are fully compliant with EU standards. Uniquely, the products do not use alcohol, which has a drying effect and can be a skin irritant. The hard surface cleaners, particularly the TrionicPlus trigger spray and Azowipe Active wipes are based on a lifting and removing concept, completely removing biofilms and cleaning to molecular level. The product continues to be active after use and cleans through oxidation action, not toxification which means that there is no need to rotate disinfectants because there is no chance of resistance developing (cf GMP guidelines). Ebiox also offers a range of products for the effective cleaning of re-usable instruments. Critically, these products remove all debris prior to the sterilisation process thereby ensuring complete decontamination. They have proven to be more effective than natural detergents and enzymatic detergents currently available. As well as the current range of products, Ebiox also has products for the decontamination of dental aspiration lines and a veterinary product range, EbioxVET. Healthcare Enterprise Group PLC HCEG is quoted on the UK AIM stock market with its head office in London and subsidiary offices in Manchester, Liverpool, Cheshire, Germany and the USA. HCEG is a business engaged in medical product distribution, occupational health, first aid and medical consultancy markets. These businesses underpin a range of innovative medical devices, which will be introduced to the market via HCEG's own distribution network on an international basis. This information is provided by RNS The company news service from the London Stock Exchange END ACQQKBKNOBKDAOB
1 Year Healthcare Enterprise Chart |
1 Month Healthcare Enterprise Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions